BRAF V600 E mutation-positive melanoma
GPTKB entity
Statements (84)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:vemurafenib
gptkb:Trametinib |
| gptkbp:belligerent |
BRAF wild-type melanoma
|
| gptkbp:can_lead_to |
metastasis
|
| gptkbp:disease_resistance |
targeted therapy
|
| gptkbp:genetic_diversity |
BRAF V600 E
|
| gptkbp:hosts |
gptkb:vaccine
MEK inhibitors |
| https://www.w3.org/2000/01/rdf-schema#label |
BRAF V600 E mutation-positive melanoma
|
| gptkbp:is_affected_by |
environmental factors
|
| gptkbp:is_associated_with |
increased mortality
patient outcomes targeted therapy tumor heterogeneity clinical outcomes specific biomarkers poor prognosis immune evasion increased tumor growth lymph node involvement |
| gptkbp:is_characterized_by |
abnormal cell growth
specific genetic alterations abnormal BRAF protein |
| gptkbp:is_considered |
aggressive
treatment guidelines a major health concern a subtype of melanoma |
| gptkbp:is_considered_as |
target for therapy
|
| gptkbp:is_described_as |
highly aggressive
|
| gptkbp:is_evaluated_by |
imaging studies
treatment response clinical research trials therapeutic studies |
| gptkbp:is_influenced_by |
genetic predisposition
|
| gptkbp:is_linked_to |
survival rates
tumor microenvironment poor prognosis treatment resistance systemic therapy adverse effects of treatment increased mutation burden increased risk of recurrence immunotherapy resistance |
| gptkbp:is_monitored_by |
follow-up care
|
| gptkbp:is_often_depicted_as |
skin lesions
|
| gptkbp:is_often_used_in |
gptkb:healthcare_organization
gptkb:BRAF_V600_K_mutation-positive_melanoma younger patients advanced melanoma |
| gptkbp:is_part_of |
gptkb:municipality
cancer research precision medicine cancer genomics cancer prevention strategies cancer treatment protocols melanoma research cancer epidemiology studies |
| gptkbp:is_protected_by |
sunscreen use
|
| gptkbp:is_recognized_by |
molecular profiling
|
| gptkbp:is_related_to |
sun exposure
|
| gptkbp:is_studied_in |
biomarker discovery
clinical trials oncology laboratory research |
| gptkbp:is_subject_to |
clinical trials
FDA approval ongoing research |
| gptkbp:is_tested_for |
genetic testing
|
| gptkbp:managed_by |
oncologists
multidisciplinary approach |
| gptkbp:occurs_in |
adults
|
| gptkbp:recognizes |
genetic testing
|
| gptkbp:scientific_classification |
stage IV melanoma
|
| gptkbp:social_responsibility |
biopsy
variable outcomes |
| gptkbp:treatment |
gptkb:vemurafenib
gptkb:hospital combination therapy targeted therapies radiation therapy BRAF inhibitors novel therapies |